CSF Biomarker May Support Lewy Body Diagnosis - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CSF Biomarker May Support Lewy Body Diagnosis

A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls

  • By

  • Henry Thomas

  • April 3, 2026

  • 2 min

Share

Original Source(s)

CSF Biomarker May Support Lewy Body Diagnosis

  • by Henry Thomas

  • April 3, 2026

Related Content

Anemia Tied to Higher Dementia Risk

Older adults with anemia showed elevated Alzheimer-related biomarkers and a higher hazard of dementia over follow-up

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

Metabolic Health Tied to Dementia

In two population-based cohorts, metabolically unhealthy status generally showed higher dementia risk estimates, while metabolically healthy obesity was not associated with increased risk in primary analyses.